Wegener's granulomatosis
Methodology & AI Transparency ⓘ
Wegener's granulomatosis Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Designated in federal medical registries as M31.30, Wegener's granulomatosis falls under Arthritis & Joints management, where synovial fluid crystal/cell in Wegener's granulomatosis (M31.30: analysis when effused) establishes baseline severity and rules out diagnostic mimics.
- 2 Real-world patient consensus: Diagnostic registry M31.30: Wegener's granulomatosis is managed within Arthritis & Joints.
- 3 Typical cash cost range: Primary evaluation for Wegener's granulomatosis incorporates synovial fluid crystal/cell in Wegener's granulomatosis (M31.30: analysis when effused) and symptom diary review.
- 4 Top reported side effects / signs: Key Arthritis & Joints biomarkers for Wegener's granulomatosis (M31.30): Weight-Bearing Joint Radiograph [Wegener's granulomatosis M31.30] & Serum Uric Acid in Wegener's granulomatosis (M31.30: (Gout Target)) (< 6.0 mg/dL (< 5.0 mg/dL with tophi) (M31.30)).
Ask our AI Specialists anything about Wegener's granulomatosis
What Is Wegener's granulomatosis?
Designated in federal medical registries as M31.30, Wegener's granulomatosis falls under Arthritis & Joints management, where synovial fluid crystal/cell in Wegener's granulomatosis (M31.30: analysis when effused) establishes baseline severity and rules out diagnostic mimics.
Pathophysiology, Underlying Causes & Clinical Presentation
Biological expression of Wegener's granulomatosis (M31.30, Arthritis & Joints) reflects monosodium urate or in Wegener's granulomatosis (M31.30: calcium pyrophosphate crystal). longitudinal control is benchmarked via Weight-Bearing Joint Radiograph [Wegener's granulomatosis M31.30].
Common Symptoms & Clinical Signs
- • Presentation of Wegener's granulomatosis (M31.30): brief morning joint in Wegener's granulomatosis (M31.30: stiffness)
- • Secondary Wegener's granulomatosis clinical sign: sudden, intensely painful, in Wegener's granulomatosis (M31.30: red swollen big-toe)
- • Symptom flares in Wegener's granulomatosis correlating with Weight-Bearing Joint Radiograph [Wegener's granulomatosis M31.30] deviation outside Preserved joint-space width (M31.30)
- • Functional arthritis & joints impact requiring synovial fluid crystal/cell in Wegener's granulomatosis (M31.30: analysis when effused) evaluation (M31.30)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Wegener's granulomatosis Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | M31.30 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Osteoarthritis, Gout & Joint Pain | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Weight-Bearing Joint Radiograph [Wegener's granulomatosis M31.30] | Preserved joint-space width (M31.30) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Serum Uric Acid in Wegener's granulomatosis (M31.30: (Gout Target)) | < 6.0 mg/dL (< 5.0 mg/dL with tophi) (M31.30) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: hs-CRP & Erythrocyte in Wegener's granulomatosis (M31.30: Sedimentation Rate) | hs-CRP < 1.5 mg/L; ESR < 15 mm/hr (M31.30) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Wegener's granulomatosis
Treatment selection for Wegener's granulomatosis depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Wegener's granulomatosis)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Bimekizumab efficacy in male and female patients with axial spondyloarthritis: Although male patients had earlier clinical responses to bimekizumab treatment, female patients demonstrated longer-term improvements in composite and patient-reported outcomes. Rheumatology (Oxford, England) • 2026-10-01 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 42605056 ↗ |
| Can This Approach Help? Inside the Latest Research on Benefits and safety of the anti-TNF multivalent NANOBODY® compound ozoralizumab Ozoralizumab demonstrated significant therapeutic effects and efficacy, which was maintained for 52 weeks. Modern rheumatology • 2023-08-25 • Phase III Randomized Trial | N = 23 | 88/100 | PMID 36197757 ↗ |
| Can This Approach Help? Inside the Latest Research on Effects of sarilumab as single-drug treatment and in combination with UP and inflammation were reduced in patients with active RA in Japan in both SAR single-drug treatment and SAR + csDMARDs treatment groups. Modern rheumatology • 2024-12-25 • Phase III Randomized Trial | N = 61 | 82/100 | PMID 39073577 ↗ |
Wegener's granulomatosis Patient Community & “People Like Me” Threads
Filter Wegener's granulomatosis community threads and patient logs by age, biological sex, dosage, and treatment duration.